Cancer Cell Biology The goal of the Cancer Cell Biology Program is to foster integrated research that spans key themes of modern cell biology, especially as they relate to cancer etiology, prevenfion and therapy, to enhance the capabilities of members through establishment or expansion of appropriate core facilities, and to promote interactions with other UNC LCCC basic, clinical and population science programs. Program research is organized around five major areas: angiogenesis &vascular biology, cell adhesion &cytoskeleton, cell cycle, cell signaling, and chromatin regulafion &epigenetics. Program highlights include the discoveries: by Yi Zhang (appointed as an Investigator of Howard Hughes Medical Institute, 2004) of the JmjC domain (JMJD) family of histone demethylases and the function of demethylase D0T1L in in leukemogenesis {Cell, 2005);by Ted Salmon (elected a member of the American Academy of Arts and Sciences, 2006) of the control and architecture of the kinetochore {Cell, 2005;Cell, 2007;Cell, 2009);by Jim Bear (appointed as Early Career Scientist by the Howard Hughes Medical Institute, 2009) of new mechanims in the control of actin architecture branching;by Henrik Dohlman of new RGS pathway components;by Bill Marzluff the key components of histone pre-mRNA processing;and by Yue Xiong of the mechanism underlying glioma-mutation of metabolic enzyme 1DH1 and acetylation of metabolic enzymes by acetylation. The Program is led by Dr. Yue Xiong, professor of Biochemistry &Biophysics, a Program member since 1993 and Leader since 2006. He is known for his studies of cell cycle control, tumor suppression and the ubiquitin pathway. At present, the Program has 47 members who have generated a total of $35.1 M (total cost) in extramural funding in 2009, including $6.1 million of NCI funding. From 2004 to 2009, the total number of publications was 1,245;10% of which were intra-programmatic and 10% were inter-programmatic. Future plans for the Program include selective recruitment in new areas, and increased emphasis on translational studies and intra- and inter-programmatic interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594123
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$151,662
Indirect Cost
$66,182
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications